Navigation Links
Chroma Announces Positive Phase I Efficacy Data for Novel Cancer Therapy CHR-2797
Date:12/13/2007

OXFORD, England, Dec. 13 /PRNewswire/ -- Chroma Therapeutics Limited, one of the UK's leading pre-IPO biotechnology companies, announced today positive data from a Phase I study with its oral, once-daily experimental cancer therapy CHR-2797 in the treatment of patients with acute myeloid leukemia (AML), myelodysplastic syndromes (MDS) and multiple myeloma (MM) who have failed on, or who are unsuitable for, chemotherapy.

Headline data from the study, which was presented by a key study investigator, Dr. Faith Davies of the Royal Marsden Hospital, London, were as follows:

-- 3 out of 13 AML patients treated in this study showed a complete

response (CR) and one further AML patient became

transfusion-independent;

-- one MM patient (out of two treated in this study) remained in stable

disease after six months of treatment with CHR-2797; and

-- the drug was very well-tolerated during the study

Chroma is currently assessing CHR-2797 in AML and MDS patients in the Phase II portion of this trial. This trial is now fully recruited and results are expected in the first half of 2008.

Ian Nicholson, Chief Executive Officer of Chroma, commented: "We are very encouraged by the efficacy we have seen in this Phase I study and look forward to further exploring how patients with this debilitating disease might be treated with CHR-2797".

An abstract of the data from this study was submitted to the recent American Society of Hematology (ASH) meeting and was subsequently selected for oral presentation. The full ASH presentation will be available at the company's website, http://www.chromatherapeutics.com.

Enquiries

Chroma Therapeutics Limited

Ian Nicholson Chief Executive Officer +44 (0)1235 829120

Richard Bungay Chief Financial Officer

Brunswick

Jon Coles
'/>"/>

SOURCE Chroma Therapeutics Limited
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
3. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
4. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
5. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
6. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
7. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
8. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
9. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
10. Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights
11. MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/31/2015)... 2015  Chiasma, Inc. (NASDAQ: CHMA ), ... for the orphan condition acromegaly, today reported financial ... 2015 and provided a corporate update. ... time for Chiasma, as we successfully completed our ... first New Drug Application (NDA) has been accepted ...
(Date:8/31/2015)... 2015 With increasing clinical applications, the ... rise in active partnerships. The primary reason for ... quantitate CD4 cell markers in human immunodeficiency virus ... New analysis from Frost ... Market ( http://www.frost.com/nf0e ), finds the market earned ...
(Date:8/31/2015)... Aug. 31, 2015  The departments of Drug and ... at Gaudenzia Concept 90 to raise awareness for International ... in Pennsylvania and help more ... on recovery through the Building Bridges to Recovery ... dying every day to a disease that is fully ...
Breaking Medicine Technology:Chiasma Reports Second Quarter 2015 Financial Results and Recent Business Highlights 2Chiasma Reports Second Quarter 2015 Financial Results and Recent Business Highlights 3Chiasma Reports Second Quarter 2015 Financial Results and Recent Business Highlights 4Chiasma Reports Second Quarter 2015 Financial Results and Recent Business Highlights 5Chiasma Reports Second Quarter 2015 Financial Results and Recent Business Highlights 6Chiasma Reports Second Quarter 2015 Financial Results and Recent Business Highlights 7Chiasma Reports Second Quarter 2015 Financial Results and Recent Business Highlights 8Chiasma Reports Second Quarter 2015 Financial Results and Recent Business Highlights 9Clinical Applications of Flow Cytometry Instrumentation and Reagents are Transforming this Market with a High-Growth Path 2Clinical Applications of Flow Cytometry Instrumentation and Reagents are Transforming this Market with a High-Growth Path 3Clinical Applications of Flow Cytometry Instrumentation and Reagents are Transforming this Market with a High-Growth Path 4Pennsylvania Departments of Drug & Alcohol Programs and Health Kick-off Second Annual Building Bridges to Recovery Initiative 2
... Identify Unique microRNA Signatures That Will ... Project Will Leverage Rosetta Genomics, Proprietary microRNA Extraction, and Quantification Technologies, ... and Experience ... Patients With High Risk, of Recurrence, who may Benefit From Adjuvant ...
... Accrual and Expansion Plans for SB-509-701 Phase 2 Clinical Trial for ... ... Neuropathy, SAN FRANCISCO, June 6 Sangamo BioSciences,Inc. (Nasdaq: SGMO ... trial (SB-509-701) in subjects with moderate to,severe diabetic neuropathy. Additionally, based upon ...
Cached Medicine Technology:Rosetta Genomics and M. D. Anderson to Develop a MicroRNA-based Diagnostic Test to Identify Risk of Recurrence of Lung Cancer 2Rosetta Genomics and M. D. Anderson to Develop a MicroRNA-based Diagnostic Test to Identify Risk of Recurrence of Lung Cancer 3Rosetta Genomics and M. D. Anderson to Develop a MicroRNA-based Diagnostic Test to Identify Risk of Recurrence of Lung Cancer 4Rosetta Genomics and M. D. Anderson to Develop a MicroRNA-based Diagnostic Test to Identify Risk of Recurrence of Lung Cancer 5Sangamo BioSciences Provides Update on Diabetic Neuropathy Clinical Programs 2Sangamo BioSciences Provides Update on Diabetic Neuropathy Clinical Programs 3Sangamo BioSciences Provides Update on Diabetic Neuropathy Clinical Programs 4Sangamo BioSciences Provides Update on Diabetic Neuropathy Clinical Programs 5
(Date:9/1/2015)... ... September 01, 2015 , ... ... of professional hair salons. This highly anticipated partnership between Curly Hair Solutions™ and ... Styling Collection. Founder Jonathan Torch and the Curly Hair Solutions™ team could not ...
(Date:8/31/2015)... ... August 31, 2015 , ... Sculpted Contours Luxury Medical Aesthetics proudly announces that ... Influence by Modern Luxury’s The Atlantan Magazine. , This award for the ... King. Her idea and vision to bring to Atlanta a true luxury experience ...
(Date:8/31/2015)... ... 31, 2015 , ... When it comes to undergoing a hair transplant, most patients have donor ... Adding more volume to the hair on top of the scalp, as well as filling ... amount of donor hair on other areas of their head. , What about patients who ...
(Date:8/31/2015)... ... August 31, 2015 , ... Women’s Excellence in ... unique to the Lake Orion area. This program is one of the most ... weight management program will incorporate group fitness and nutritional consultations to help people ...
(Date:8/31/2015)... ... ... Coast Dental Vista is celebrating its recent grand opening with ... near Albertsons in the Foothill Center, located at 1279 E. Vista Way. There will ... Lopp. Call (760) 208-2518 for more details or stop by on September 5. , ...
Breaking Medicine News(10 mins):Health News:Curly Hair Solutions™ Partners With Trade Secrets 2Health News:Sculpted Contours Owner Selected One of Atlanta's Women of Power and Influence by Modern Luxury's The Atlantan Magazine 2Health News:Sculpted Contours Owner Selected One of Atlanta's Women of Power and Influence by Modern Luxury's The Atlantan Magazine 3Health News:Body Hair Transplants to Help Achieve a Full Head of Hair 2Health News:Discover How to Replace Missing Teeth, Reduce Cavities, and Restore Oral Health During Coast Dental’s Open House in Vista, CA on Sept. 5, 2015 2Health News:Discover How to Replace Missing Teeth, Reduce Cavities, and Restore Oral Health During Coast Dental’s Open House in Vista, CA on Sept. 5, 2015 3
... (2DE) is the most cost-effective protein profiling technology and ... a protein sample can be entirely visualised in a ... be effectively tackled for these advantages to be leveraged ... (Logo: http://www.newscom.com/cgi-bin/prnh/20081117/FSLOGO ) , , New analysis ...
... HONG KONG, June 30 /PRNewswire-Asia-FirstCall/ ... Stock Code: 801.HK), a leading,hi-tech medical device and healthcare ... the year ended 31 March 2009. During the year,the ... the core businesses,but also successfully listed its cord blood ...
... ... entertain pre and post operative weight loss surgery patients, BariatricTV.com provided video taped coverage ... and service to the bariatric community as well as an informative interview with Dr. ... (OAC). , ...
... ... partner with Mission Predisan, a Christian, not-for-profit organization, to sponsor two, one week medical ... ... is pleased to partner with Mission Predisan, a Christian, not-for-profit organization, to sponsor two, ...
... , ... leader, and current editor-in-chief of Orthopaedic Knowledge Online, William A. Grana, MD, MPH, will ... of Fame, Friday, July 11th during its Annual Meeting in Keystone, Colorado. ... Keystone, CO (Vocus) ...
... ... be installed as the 38th president of the American Orthopaedic Society for Sports ... Keystone, Colorado (July 9th-12th). , ... Keystone, CO (Vocus) June 30, 2009 -- Internationally recognized, orthopaedic surgeon, ...
Cached Medicine News:Health News:Growing Proteomics Market and the Current Economic Crisis Could Act in Tandem to Spur Growth in the European 2 Dimensional Gel Electrophoresis Market, States Frost & Sullivan 2Health News:Growing Proteomics Market and the Current Economic Crisis Could Act in Tandem to Spur Growth in the European 2 Dimensional Gel Electrophoresis Market, States Frost & Sullivan 3Health News:Golden Meditech Announces Financial Year 2008/09 Annual Results 2Health News:Golden Meditech Announces Financial Year 2008/09 Annual Results 3Health News:BariatrivTV.com Educates and Entertains Weight Loss Surgery Patients with Coverage of the American Society for Metabolic and Bariatric Surgery Meeting 2Health News:BariatrivTV.com Educates and Entertains Weight Loss Surgery Patients with Coverage of the American Society for Metabolic and Bariatric Surgery Meeting 3Health News:Mission Predisan and Jackson Healthcare (JH) Partner for Medical Missions 2Health News:Mission Predisan and Jackson Healthcare (JH) Partner for Medical Missions 3Health News:Teacher and Profession Leader, William A. Grana, MD, MPH, Inducted into Sports Medicine Hall of Fame 2Health News:Teacher and Profession Leader, William A. Grana, MD, MPH, Inducted into Sports Medicine Hall of Fame 3Health News:James R. Andrews, Renowned Orthopaedic Surgeon, Installed as AOSSM President 2Health News:James R. Andrews, Renowned Orthopaedic Surgeon, Installed as AOSSM President 3
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: